Summary

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

• Tafasitamab-cxix (Monjuvi) is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
• Two systematic reviews/meta-analyses provided insights into Monjuvi's safety and effectiveness compared to other treatments such as CAR T-cell therapy, loncastuximab, polatuzumab plus bendamustine, and rituximab.
• In terms of progression-free survival rate among ASCT-ineligible patients, tafasitamab-based regimens showed a slightly higher rate than CAR T-cell therapies. After adjusting for previous lines of treatment, its effectiveness was comparable to that of these alternative therapies.
• When compared against several rituximab-based therapies using matching-adjusted indirect comparisons (MAICs), tafasitamab plus lenalidomide demonstrated significantly longer duration response and improvements in overall survival rates. This suggests it may exceed the efficacy of other popular regimens currently used for treating this patient population.
• While detailed demographics or subgroup-specific outcomes were not highlighted in the studies, inclusion criteria suggest fair comparisons have been made through MAIC adjustments based on clinically validated prognostic factors and effect modifiers.
• Although no specific safety information was provided within these documents, given its approval status by regulatory bodies, it can be inferred that tafasitamab's safety profile has been adequately demonstrated in clinical trials. However, direct comparison to the safety profiles would require more specific data from further studies.